Research Misconduct Examples: Why Reports Hide

Research misconduct examples are well documented in scholarly literature and case databases, but the investigation reports that actually establish them almost never reach the public. In the UK and the US, institutions overwhelmingly keep findings, evidence and reasoning confidential even after a case closes — a practice that a small number of national bodies elsewhere have abandoned in favour of publishing final rulings.

Research misconduct is fabrication, falsification, or plagiarism in proposing, performing, reviewing, or reporting research, as defined by the US Office of Research Integrity under 42 CFR Part 93. That definition is narrow by design. It is also, this piece argues, too often the only thing the public is allowed to see — the “what” without the “how we know.”

• What is research misconduct? Definitions and examples
• Why do institutions keep investigation reports confidential?
• How do more transparent regimes handle disclosure?
• What does the secrecy cost — and what should change?
• Common questions on research misconduct

What is research misconduct? Definitions and examples

Fabrication, falsification and plagiarism — FFP — form the internationally recognised core of research misconduct, used by the US Office of Research Integrity (ORI), the UK Research Integrity Office (UKRIO), and the Committee on Publication Ethics (COPE). Fabrication means inventing data or results outright. Falsification means manipulating materials, equipment, images or data so the record misrepresents what actually happened. Plagiarism means presenting someone else’s ideas, data or words as one’s own without attribution.

Beyond the FFP core, most UK institutional policies and UKRIO’s own guidance extend coverage to related breaches that damage the research record without always meeting the strict fabrication-falsification-plagiarism test:

• Undisclosed conflicts of interest that could plausibly bias findings or peer review
• Inappropriate authorship — denying credit to real contributors or granting it to non-contributors, a problem CASRAI’s contributor-role work in CRediT was originally built to address
• Redundant or “salami-sliced” publication of the same dataset across multiple papers
• Manipulation of the peer-review process, including fabricated reviewer identities
• Paper-mill involvement — buying or selling fraudulent manuscripts dressed as original research

Retraction Watch’s public database tracks the downstream signal of these failures — the retraction itself — but a retraction notice rarely explains what an investigation found. That gap between “a paper was retracted” and “here is the evidence” is the transparency problem this article addresses.

Why do institutions keep investigation reports confidential?

UK and US institutions cite broadly consistent reasons for withholding full reports, and some are genuinely legitimate. None justifies blanket non-disclosure once a case is closed and a finding is made.

• Personnel-record status. Many US institutions classify misconduct files as personnel records, exempting them from public-records requests even at public universities.
• Whistleblower protection. Confidentiality during an inquiry is defensible — it protects the person who raised the concern from retaliation while facts are established.
• Reputational risk to the accused. Institutions worry that publishing findings, even redacted ones, will follow a researcher regardless of outcome.
• Litigation exposure. Legal teams treat investigation reports as liability documents first and research-integrity documents second.
• No statutory disclosure duty. Unlike the US, where ORI’s federal oversight of Public Health Service-funded research creates a disclosure mechanism, the UK has no national body with investigatory or publication powers.

The UK’s 2019 Concordat to Support Research Integrity, coordinated by Universities UK, commits signatory institutions to publish an annual statement on how many misconduct allegations they received and investigated. It does not require publication of the underlying reports. This is the crux of the transparency debate: aggregate counts satisfy the letter of accountability while the substance — what was actually found, and how — stays locked in a drawer.

The US system looks more transparent at first glance because ORI’s Case Summaries register is genuinely public. Read the fine print, though, and the scope narrows sharply: it covers only Public Health Service-funded research, only cases where ORI itself made a finding (institutions handle the great majority internally, without ORI referral), and only researchers currently serving an active administrative sanction — historical entries are removed once the sanction period expires.

How do more transparent regimes handle disclosure?

A handful of national systems have made a different bet: that publishing final misconduct decisions, with personal data appropriately redacted, strengthens rather than undermines trust in the research system.

Denmark and Norway share a structural feature the UK and US both lack: a single national committee with statutory authority to investigate and to publish. That centralisation removes the conflict of interest built into the UK and US model, where the institution investigating its own researcher is also the institution deciding whether the findings ever see daylight.

What does the secrecy cost — and what should change?

Withholding investigation reports has three concrete costs. First, it prevents the research community from learning the specific mechanics of a case — which is precisely what field-level prevention requires. A retraction notice reading “concerns about data integrity” teaches almost nothing; a published finding detailing exactly which images were duplicated, or which patient records were invented, teaches a field how the fraud was constructed and how it was caught.

Second, it fuels distrust in the institutions research administrators run. When a case surfaces only through journalism or a whistleblower’s own account — rather than the institution’s — the institution looks like it concealed wrongdoing rather than corrected it, whatever the reality.

Third, it weakens deterrence. Sanctions that never become public carry a materially smaller reputational cost, changing the incentive calculation for researchers weighing whether to cut corners.

None of this requires abandoning legitimate protections. A workable model — closer to Denmark’s than the UK’s current default — would:

1. Publish final findings only, after due process concludes, never mid-investigation
2. Redact personal data unrelated to the finding itself, while naming the researcher where a finding of misconduct is confirmed and sanctioned, consistent with COPE’s retraction guidelines
3. Separate the publication decision from the investigating institution, ideally through a national or sector body — the role UKRIO could grow into if given statutory footing
4. Require research integrity offices to log outcomes in a format compatible with existing registries, including Retraction Watch’s database and journals’ own correction records

UKRIO’s current remit is advisory, not investigatory — it cannot compel disclosure. Extending it, or creating a UK equivalent of Denmark’s committee, would close the gap between the UK’s stated commitment to research integrity and its practice of keeping the evidence for that commitment confidential.

Common questions on research misconduct

What counts as research misconduct?

Research misconduct is fabrication, falsification, or plagiarism in proposing, performing, reviewing, or reporting research. It excludes honest error and genuine differences of scientific opinion. UK guidance from the UK Research Integrity Office also treats undisclosed conflicts of interest and data manipulation as misconduct.

What are the three types of research misconduct?

The three internationally recognised types are fabrication (inventing data), falsification (manipulating materials or altering results), and plagiarism (presenting others’ work as one’s own). This FFP framework, used by ORI and COPE, deliberately excludes honest error and normal scientific disagreement.

What is considered the most serious form of research misconduct?

Fabrication is generally treated as the most severe form because it invents an entire dataset or result rather than distorting a real one. In practice, sanctions are often harshest for falsification in clinical or biomedical research, where fabricated or altered findings carry direct patient-safety consequences.

Investigation-report secrecy is a policy choice, not a technical necessity. Denmark and Norway show that publication and due process are compatible; the UK’s Concordat shows that aggregate transparency, absent case-level disclosure, is not the same thing as accountability. Research administrators and research integrity offices weighing their own disclosure policy now have a working alternative model to point to, not just a set of reasons to say no.